TD Cowen Downgrades Day One Biopharmaceuticals (DAWN) to Hold: "justifiable acquisition value"
Tweet Send to a Friend
TD Cowen analyst Tara Bancroft downgraded Day One Biopharmaceuticals (NASDAQ: DAWN) from Buy to Hold with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
